Figure 4: Cardiovascular complications in patients receiving enalapril or nisoldipine [74]. After 4 years of follow-up, hypertensive patients with diabetes randomly assigned to the angiotensin-converting-enzyme inhibitor enalapril had significantly fewer cardiovascular complications than those randomly assigned to the calcium channel blocker nisoldipine. Abbreviations: CV, cardiovascular; MI, myocardial infarction.